Jyong Biotech Ltd【MENS】株式ニュース

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview

New Taipei City, Taiwan, May 29, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or...

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025

New Taipei City, Taiwan, May 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or...

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form NT 20-F - Notification of inability to timely file Form 20-F

Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio

New Taipei City, Taiwan, April 28, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”...

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

Form 3 - Initial statement of beneficial ownership of securities

Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2

New Taipei City, Taiwan, March 27, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”...

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

- Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer...

glenn1919 4月前

MENS....................https://stockcharts.com/sc3/ui/?s=MEN&Sp=w&b=5&g=0&id=p86431144783

👍️0

glenn1919 4月前

MENS....................................https://stockcharts.com/sc3/ui/?s=MENS&p=w&b=5&g=0&id=p86431144783

👍️0

glenn1919 4月前

MENS...................................................https://stockcharts.com/sc3/ui/?s=MENS&p=w&b=5&g=0&id=p86431144783

👍️0

makinezmoney 4月前

$MENS: I see it rolling....... now $2

This could be the start of that rebound !!!!!!!!!!!!

GO $MENS

👍️0

hondaboost 6月前

MENS O/S: 2.6 m, tiny! IPO at $7.5 here:

New Taipei City, Taiwan, June 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (the “Company”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced the pricing of its initial public offering (the “Offering”) of 2,666,667 ordinary shares (the “Ordinary Shares”) at a public offering price of $7.50 per share. The Company expects to receive aggregate gross proceeds of approximately $20 million, before deducting underwriting discounts and other offering expenses. The Ordinary Shares have been approved for listing on the Nasdaq Global Market and are expected to commence trading on June 17, 2025 under the ticker symbol “MENS”. The Offering is expected to close on June 18, 2025, subject to the satisfaction of customary closing conditions. In addition, the Company has granted the underwriters an option (the "Over-Allotment Option"), within 45 days from the date of the final prospectus, to purchase up to an additional 400,000 Ordinary Shares at the public offering price, less underwriting discounts, to cover the Over-Allotment Option, if any.

👍 1

hondaboost 6月前

MENS, from $67 to $3 ? Irrational movements!

👍 1

makinezmoney 6月前

$MENS: Insiders completely unloaded.......... now $3

Was $16 yesterday

CHINNnnnnnerrrrrrrrrssssssssssssssssssssssssssssssssssssss

GO $MENS

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Jyong Biotech Ltd (MENS)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

Jyong Biotech Ltd (MENS) ニュース

Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form NT 20-F - Notification of inability to timely file Form 20-F

Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

MENS Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Jyong Biotech Ltd (MENS)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

Jyong Biotech Ltd (MENS) ニュース

Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form NT 20-F - Notification of inability to timely file Form 20-F

Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

MENS Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する